JO3820B1 - أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها - Google Patents

أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها

Info

Publication number
JO3820B1
JO3820B1 JOP/2013/0131A JOP20130131A JO3820B1 JO 3820 B1 JO3820 B1 JO 3820B1 JO P20130131 A JOP20130131 A JO P20130131A JO 3820 B1 JO3820 B1 JO 3820B1
Authority
JO
Jordan
Prior art keywords
span
rtl
dir
antibodies
fel
Prior art date
Application number
JOP/2013/0131A
Other languages
English (en)
Inventor
Andrew J Murphy
Jamie Orengo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3820(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3820B1 publication Critical patent/JO3820B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بتوفير أجسام مضادة ترتبط بمولد حساسية من هرة، </span>Fel d1<span dir="RTL">، وتركيبات تتضمن تلك الاجسام المضادة، وأحماض نووية تشفر الأجسام المضادة وطرق لاستخدام تلك الأجسام المضادة. وفقا لنماذج معينة من الاختراع، تعد الأجسام المضادة عبارة عن أجسام مضادة أحادية النسيلة بشرية كاملة ترتبط بـ </span>Fel d1<span dir="RTL">، تعد الأجسام المضادة وفق الاختراع مفيدة للارتباط بمولد الحساسية </span>Fel d1<span dir="RTL"> في الجسم الحي، بما يمنع الارتباط بمولد الحساسية </span>Fel d1<span dir="RTL"> بـ </span>IgE<span dir="RTL"> متكون سلفا على سطح الخلايا البدينة أو الخلايا القاعدية. بذلك، تعمل الأجسام المضادة على منع إطلاق الهيستامين والعوامل الوسيطة الالتهابية الأخرى من الخلايا البدينة و/أو الخلايا القاعدية، بما يخفف من استجابة غير مستحبة لمسبب الحساسية من هرة في الأفراد المصابين بالحساسية. يمكن كذلك أن تكون الأجسام المضادة وفق الاختراع مفيدة لأغراض تشخيصية لتحديد ما إن كان المريض حساس لمسبب الحساسية من هرة </span>Fel d1<span dir="RTL">.</span>
JOP/2013/0131A 2012-05-03 2013-05-01 أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها JO3820B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642083P 2012-05-03 2012-05-03
US201261718044P 2012-10-24 2012-10-24
US201361783312P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3820B1 true JO3820B1 (ar) 2021-01-31

Family

ID=48326501

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0131A JO3820B1 (ar) 2012-05-03 2013-05-01 أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها

Country Status (33)

Country Link
US (6) US9079948B2 (ar)
EP (4) EP3978522B1 (ar)
JP (2) JP6400569B2 (ar)
KR (1) KR102185516B1 (ar)
CN (2) CN110240651B (ar)
AR (1) AR090914A1 (ar)
AU (2) AU2013256251C1 (ar)
BR (2) BR112014026852B1 (ar)
CA (1) CA2871077C (ar)
CY (2) CY1124023T1 (ar)
DK (2) DK3978522T3 (ar)
ES (3) ES2780392T3 (ar)
FI (1) FI3978522T3 (ar)
HR (3) HRP20200652T1 (ar)
HU (2) HUE049440T2 (ar)
IL (1) IL235121B (ar)
IN (1) IN2014DN08767A (ar)
JO (1) JO3820B1 (ar)
LT (3) LT2844672T (ar)
MX (2) MX377634B (ar)
MY (3) MY181422A (ar)
NZ (2) NZ701124A (ar)
PL (3) PL3660047T3 (ar)
PT (3) PT3660047T (ar)
RS (3) RS62636B1 (ar)
RU (1) RU2658491C2 (ar)
SG (3) SG10201608378UA (ar)
SI (3) SI3978522T1 (ar)
SM (3) SMT202200014T1 (ar)
TW (2) TWI644921B (ar)
UY (1) UY34782A (ar)
WO (1) WO2013166236A1 (ar)
ZA (3) ZA201407302B (ar)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
HK1255206A1 (zh) * 2015-09-08 2019-08-09 苏黎世大学 抗猫过敏的组合物
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
RS67826B1 (sr) * 2016-12-22 2026-03-31 Regeneron Pharma Postupak za lečenje alergije sa monoklonskim antitelima specifičnim za alergen
JP7112409B2 (ja) * 2017-01-24 2022-08-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 抗Ｆｅｌ Ｄ１抗体を含む組成物及びヒトのネコアレルギーの少なくとも１つの症状を減少させる方法
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
MX2020006639A (es) 2017-12-22 2020-09-14 Regeneron Pharma Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
BR112020013336A2 (pt) 2018-01-31 2020-12-01 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
WO2019168774A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
HUE065344T2 (hu) 2018-03-19 2024-05-28 Regeneron Pharma Mikrochip kapilláris elektroforézis assay-k és reagensek
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
JP2021525070A (ja) * 2018-05-18 2021-09-24 チャン ザッカーバーグ バイオハブ， インコーポレイテッド ヒト由来のアレルゲン特異的抗体を単離する方法およびその使用
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP7511542B2 (ja) 2018-08-30 2024-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質複合体を特徴づけるための方法
WO2020150491A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
WO2021061790A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CA3158119A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN115398236B (zh) 2020-01-21 2024-06-11 瑞泽恩制药公司 用于糖基化的蛋白质的电泳的去糖基化方法
WO2022046925A1 (en) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
EP4305190A4 (en) 2021-03-11 2025-03-26 Iggenix, Inc. METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION
AU2022243005A1 (en) 2021-03-26 2023-10-05 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
CN114113278B (zh) * 2021-11-24 2024-08-02 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
KR20240164561A (ko) 2022-03-18 2024-11-19 리제너론 파아마슈티컬스, 인크. 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템
WO2023250419A1 (en) 2022-06-23 2023-12-28 Regeneron Pharmaceuticals, Inc. Methods of identifying and evaluating cat allergy gene signatures in a subject by determining a stratified score based on gene expression
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
IL322811A (en) 2023-03-01 2025-10-01 Regeneron Pharma Anti-FEL D1 antibody formulations
EP4688165A1 (en) 2023-03-31 2026-02-11 ALK-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
US20240366471A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117069865B (zh) * 2023-10-12 2024-03-01 中国农业科学院饲料研究所 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
CN117964767B (zh) * 2024-03-29 2024-08-06 北京恩泽康泰生物科技有限公司 抗rage抗体、细胞外囊泡及其制备方法和应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
CA2128331A1 (en) 1992-01-21 1993-07-22 Julia L. Greenstein Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
WO1994014475A1 (en) * 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ZA200707413B (en) * 2005-03-18 2009-01-28 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
GB0513878D0 (en) * 2005-07-06 2005-08-10 Mars Inc Cat allergen
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
WO2007113633A2 (en) * 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1921142A1 (en) * 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
ES2593484T3 (es) * 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
ES2599639T3 (es) * 2007-07-09 2017-02-02 Nestec S.A. Procedimientos para reducir las alergias causadas por alérgenos ambientales
MX2010001395A (es) * 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
RS67826B1 (sr) 2016-12-22 2026-03-31 Regeneron Pharma Postupak za lečenje alergije sa monoklonskim antitelima specifičnim za alergen

Also Published As

Publication number Publication date
EP3978522A3 (en) 2022-07-06
JP2017153491A (ja) 2017-09-07
JP2015523962A (ja) 2015-08-20
AU2018203087B2 (en) 2020-03-12
SMT202200014T1 (it) 2022-03-21
SG10201608378UA (en) 2016-11-29
UY34782A (es) 2013-11-29
NZ701124A (en) 2017-07-28
ZA202005273B (en) 2023-11-29
ES2780392T3 (es) 2020-08-25
HRP20211932T1 (hr) 2022-03-18
US10047152B2 (en) 2018-08-14
WO2013166236A1 (en) 2013-11-07
US11174305B2 (en) 2021-11-16
SI3660047T1 (sl) 2021-12-31
EP3660047A1 (en) 2020-06-03
HUE057062T2 (hu) 2022-04-28
SI2844672T1 (sl) 2020-07-31
BR112014026852A2 (pt) 2017-07-18
MX2014013371A (es) 2015-02-05
MY164101A (en) 2017-11-30
FI3978522T3 (fi) 2025-11-13
SMT202000241T1 (it) 2020-07-08
LT3978522T (lt) 2025-11-25
KR20150005666A (ko) 2015-01-14
HRP20200652T1 (hr) 2020-07-10
US20180305446A1 (en) 2018-10-25
CA2871077C (en) 2021-08-17
US20220025029A1 (en) 2022-01-27
CN110240651B (zh) 2024-03-08
EP2844672B1 (en) 2020-02-12
EP3978522A2 (en) 2022-04-06
AU2018203087A1 (en) 2018-05-24
IL235121A0 (en) 2014-12-31
CY1124819T1 (el) 2022-11-25
CN110240651A (zh) 2019-09-17
JP6400569B2 (ja) 2018-10-03
ES2898372T3 (es) 2022-03-07
EP3660047B1 (en) 2021-10-13
CA2871077A1 (en) 2013-11-07
SG10202102919XA (en) 2021-05-28
RU2658491C2 (ru) 2018-06-21
SG11201406748QA (en) 2014-11-27
BR112014026852B1 (pt) 2023-01-03
US20170210790A1 (en) 2017-07-27
DK3978522T3 (da) 2025-10-27
CY1124023T1 (el) 2022-03-24
EP3978522B1 (en) 2025-10-01
AU2013256251A1 (en) 2014-11-06
US10047153B2 (en) 2018-08-14
CN104411719B (zh) 2019-05-14
HRP20251429T1 (hr) 2026-01-02
MY195564A (en) 2023-02-02
MY181422A (en) 2020-12-21
PL3978522T3 (pl) 2026-01-05
SI3978522T1 (sl) 2025-11-28
KR102185516B1 (ko) 2020-12-02
HK1202123A1 (en) 2015-09-18
TWI644921B (zh) 2018-12-21
PT3660047T (pt) 2021-11-30
IL235121B (en) 2019-06-30
JP6603269B2 (ja) 2019-11-06
PT3978522T (pt) 2025-10-17
US20130295097A1 (en) 2013-11-07
HUE049440T2 (hu) 2020-09-28
EP4653056A2 (en) 2025-11-26
RS67417B1 (sr) 2025-12-31
LT3660047T (lt) 2021-11-10
ZA202202846B (en) 2023-11-29
NZ733480A (en) 2019-03-29
SMT202500396T1 (it) 2025-11-10
US20150299303A1 (en) 2015-10-22
AU2018203087B9 (en) 2020-03-26
PL3660047T3 (pl) 2022-02-14
LT2844672T (lt) 2020-04-10
IN2014DN08767A (ar) 2015-05-22
CN104411719A (zh) 2015-03-11
RU2014148502A (ru) 2016-06-27
ZA201407302B (en) 2021-08-25
US9079948B2 (en) 2015-07-14
AU2013256251B2 (en) 2018-04-12
MX2020003864A (es) 2020-08-13
TW201803901A (zh) 2018-02-01
PL2844672T3 (pl) 2020-08-10
EP2844672A1 (en) 2015-03-11
US20160376358A1 (en) 2016-12-29
RS60282B1 (sr) 2020-06-30
AR090914A1 (es) 2014-12-17
BR122019023685B1 (pt) 2023-01-17
RS62636B1 (sr) 2021-12-31
TW201406779A (zh) 2014-02-16
DK2844672T3 (da) 2020-04-20
US9475869B2 (en) 2016-10-25
AU2013256251C1 (en) 2018-08-23
MX377634B (es) 2025-03-10
US12252530B2 (en) 2025-03-18
ES3049982T3 (en) 2025-12-19
PT2844672T (pt) 2020-04-30

Similar Documents

Publication Publication Date Title
JO3820B1 (ar) أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
Bondi et al. Found in translation: understanding the biology and behavior of experimental traumatic brain injury
Terzieva et al. Early pregnancy human decidua is enriched with activated, fully differentiated and pro-inflammatory gamma/delta T cells with diverse TCR repertoires
CL2019003508A1 (es) Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos.
BR112012013038A2 (pt) mutantes fc de anticorpo com funções efetoras ablacionadas
PT2928923T (pt) Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
WO2011094259A3 (en) Cd127 binding proteins
PT2905030T (pt) Anticorpos humanos que ligam ao gene de ativação de linfócitos 3 (lag-3) e utilizações dos mesmos
UA113609C2 (xx) Антигензв&#39;язуючий білок, який зв&#39;язує людський il-23
NZ594514A (en) Interleukin-17 BINDING PROTEINS
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
EP2525813A4 (en) ANTIBODIES TO ILT5 AND ILT5 BINDING ANTIBODY FRAGMENTS
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EP2652506A4 (en) USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
TR201904882T4 (tr) Tıbbi kullanım için bispesifik antikorlar.
WO2014120975A8 (en) Antibody-mediated immunocontraception
CN104853774A8 (zh) Il-20拮抗剂用于治疗肝脏疾病
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Suzuki et al. Basic and clinical immunology–3022. Inhibitory action of fexofenadine hydrochloride on mast cell activation in vitro
Hilger et al. Allergy to hamster-4 case reports
de León Muñoz Quality and culture of health
Grainger Immune modulation by parasitic nematodes
Morozenko et al. NORMATIVE BIOCHEMICAL INDICES OF BLOOD SERUM DOMESTIC CATS’: MODERN VIEW ON THE PROBLEM